Lexaria Reports 566% Increase in CBD Brain Absorption in Animal Study

Lexaria Bioscience announced results from animal study GLP-1-A26-1 on October 15, 2026, showing improved brain absorption with experimental DehydraTECH-CBD formulations. The ALT2 CBD formulation increased mean brain absorption by 566% versus the reference formulation eight hours after dosing. All three alternative CBD formulations showed no statistically significant differences in blood plasma absorption versus the reference, supporting potential development. The ALT2 semaglutide formulation performed best among alternatives, with no statistically significant difference in blood plasma absorption versus the reference. Three new patent applications cover tested formulations, expanding intellectual property options for commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via (Ref. ID: 202610150910ACCESSWRNAPR_____1237045) on O